title: Selective inhibition of cholesterol biosynthesis in brain cells by squalestatin 1.
abstract: The effect of squalestatin 1 (SQ) on squalene synthase and other enzymes utilizing farnesyl pyrophosphate (F-P-P) as substrate was evaluated by in vitro enzymological and in vivo metabolic labeling experiments to determine if the drug selectively inhibited cholesterol biosynthesis in brain cells. Direct in vitro enzyme studies with membrane fractions from primary cultures of embryonic rat brain (IC50 = 37 nM), pig brain (IC50 = 21 nM), and C6 glioma cells (IC50 = 35 nM) demonstrated that SQ potently inhibited squalene synthase activity but had no effect on the long-chain cis-isoprenyltransferase catalyzing the conversion of F-P-P to polyprenyl pyrophosphate (Poly-P-P), the precursor of dolichyl phosphate (Dol-P). SQ also had no effect on F-P-P synthase; the conversion of [3H]F-P-P to geranylgeranyl pyrophosphate (GG-P-P) catalyzed by partially purified GG-P-P synthase from bovine brain; the enzymatic farnesylation of recombinant H-p21ras by rat brain farnesyltransferase; or the enzymatic geranylgeranylation of recombinant Rab 1A, catalyzed by rat brain geranylgeranyltransferase. Consistent with SQ selectively blocking the synthesis of squalene, when C6 glial cells were metabolically labeled with [3H]mevalonolactone, the drug inhibited the incorporation of the labeled precursor into squalene and cholesterol (IC50 = 3-5 microM) but either had no effect or slightly stimulated the labeling of Dol-P, ubiquinone (CoQ), and isoprenylated proteins. These results indicate that SQ blocks cholesterol biosynthesis in brain cells by selectively inhibiting squalene synthase.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Biochemistry, University of Kentucky College of Medicine, Lexington.
authors.forename: D C
authors.initials: DC
authors.lastname: Crick
authors.forename: J
authors.initials: J
authors.lastname: Suders
authors.forename: C M
authors.initials: CM
authors.lastname: Kluthe
authors.forename: D A
authors.initials: DA
authors.lastname: Andres
authors.forename: C J
authors.initials: CJ
authors.lastname: Waechter
mesh_terms: D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology*; D019086:Bridged Bicyclo Compounds, Heterocyclic; D002462:Cell Membrane / Q000201:enzymology; D002478:Cells, Cultured; D002784:Cholesterol / Q000096:biosynthesis*; D004622:Embryo, Mammalian; D013186:Farnesyl-Diphosphate Farnesyltransferase / Q000037:antagonists & inhibitors; D008798:Mevalonic Acid / Q000031:analogs & derivatives / Q000378:metabolism; D017368:Protein Prenylation / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D013185:Squalene / Q000037:antagonists & inhibitors / Q000378:metabolism; D014233:Tricarboxylic Acids / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D001643:Bridged Bicyclo Compounds; D019086:Bridged Bicyclo Compounds, Heterocyclic; D014233:Tricarboxylic Acids; C075117:squalestatin 1; C015367:mevalonolactone; D013185:Squalene; D002784:Cholesterol; D013186:Farnesyl-Diphosphate Farnesyltransferase; D008798:Mevalonic Acid